Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Lee

Showing results (521-530 of 594) with videos related to

Pageof 60
Sort By:
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
The Lancet. Oncology|October 30, 2016
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R Gomez, George R Blumenschein, J Jack Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2021
Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDCBita Sahaf, Mina Pichavant, Brian H Lee, et al.
Cancer Discovery|May 16, 2012
The BATTLE trial: personalizing therapy for lung cancerEdward S Kim, Roy S Herbst, Ignacio I Wistuba, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 18, 2018
A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast DiseaseAyca Gucalp, Xi K Zhou, Elise D Cook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2022
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell CarcinomaTrisha M Wise-Draper, Shuchi Gulati, Sarah Palackdharry, et al.
Nature Communications|July 29, 2022
Mouse fetal growth restriction through parental and fetal immune gene variation and intercellular communications cascadeGurman Kaur, Caroline B M Porter, Orr Ashenberg, et al.
Carcinogenesis|April 2, 2005
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer typesAmanda Ewart-Toland, Qi Dai, Yu-Tang Gao, et al.
JAMA Oncology|November 6, 2015
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical TrialWilliam N William, Vassiliki Papadimitrakopoulou, J Jack Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|May 22, 2026
Long-term outcomes after proton therapy vs. intensity-modulated photon radiotherapy with concurrent chemotherapy for locally advanced non-small-cell lung cancer: post-hoc analysis of a prospective randomized trialTingshi Su, Ting Xu, Mei Chen, et al.
Pageof 60

Showing results (521-530 of 594) with videos related to

Sort By:
Pageof 60
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
The Lancet. Oncology|October 30, 2016
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R Gomez, George R Blumenschein, J Jack Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2021
Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDCBita Sahaf, Mina Pichavant, Brian H Lee, et al.
Cancer Discovery|May 16, 2012
The BATTLE trial: personalizing therapy for lung cancerEdward S Kim, Roy S Herbst, Ignacio I Wistuba, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 18, 2018
A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast DiseaseAyca Gucalp, Xi K Zhou, Elise D Cook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2022
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell CarcinomaTrisha M Wise-Draper, Shuchi Gulati, Sarah Palackdharry, et al.
Nature Communications|July 29, 2022
Mouse fetal growth restriction through parental and fetal immune gene variation and intercellular communications cascadeGurman Kaur, Caroline B M Porter, Orr Ashenberg, et al.
Carcinogenesis|April 2, 2005
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer typesAmanda Ewart-Toland, Qi Dai, Yu-Tang Gao, et al.
JAMA Oncology|November 6, 2015
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical TrialWilliam N William, Vassiliki Papadimitrakopoulou, J Jack Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|May 22, 2026
Long-term outcomes after proton therapy vs. intensity-modulated photon radiotherapy with concurrent chemotherapy for locally advanced non-small-cell lung cancer: post-hoc analysis of a prospective randomized trialTingshi Su, Ting Xu, Mei Chen, et al.
Pageof 60